Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Postexposure Prophylaxis to Prevent Hepatitis B Virus Infection
This appendix provides guidelines for management of
persons with nonoccupational exposure to hepatitis B virus
(HBV) through a discrete, identifiable exposure to blood or body fluids (Table). Guidelines for postexposure prophylaxis
of occupational exposures have been published separately
(1) and are intended for use in settings in which postvaccination
testing is recommended for certain employees (see Appendix A, Postvaccination Testing for
Serologic Response) and in which programs are available to implement testing and follow-up algorithms. Recommendations for management of infants born
to hepatitis B surface antigen (HBsAg)--positive mothers also have been published separately
HBsAg-Positive Exposure Source
Persons who have written documentation of a complete hepatitis B vaccine series and who did not receive postvaccination testing should receive a single vaccine booster dose.
Persons who are in the process of being vaccinated but who have not completed the vaccine series should receive
the appropriate dose of hepatitis B immune globulin (HBIG) and should complete the vaccine series.
Unvaccinated persons should receive both HBIG and hepatitis B vaccine as soon as possible after exposure
(preferably within 24 hours). Hepatitis B vaccine may be
administered simultaneously with HBIG in a separate
injection site. The hepatitis B vaccine series should be completed in accordance with the age-appropriate vaccine dose and schedule (see
Table 2 and Box 5).
Exposure Source with Unknown HBsAg Status
Persons with written documentation of a complete
hepatitis B vaccine series require no further treatment.
Persons who are not fully vaccinated should complete the vaccine series.
Unvaccinated persons should receive the hepatitis B vaccine series with the first dose administered as soon as possible
after exposure, preferably within 24 hours. The vaccine series should be completed in accordance with the
age-appropriate dose and schedule (see Table 2 and Box 5).
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to